Myriad HRD test is a next generation sequencing-based (NGS) test that assesses the qualitative detection and classification of single nucleotide variants, insertions and deletions, and large rearrangement variants in protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes and the determination of Genomic Instability Score (GIS) which is an algorithmic measurement of Loss of Heterozygosity (LOH), Telomeric Allelic Imbalance (TAI), and Large-scale State Transitions (LST) on formalin-fixed paraffin embedded (FFPE) tumor tissue specimens. The gene discussed is BRCA1; the disease is neoplasm.